Orlistat: Clinical Trials

16 trials of Orlistat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 3 not yet recruiting, 2 terminated, 2 unknown. 16 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 216Completed 8, Not yet recruiting 3, Terminated 2, Unknown 2, Recruiting 1
Phase 11Completed 1

Follow Orlistat: new trials by email Literature Review of Orlistat trials Research Report on Orlistat

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia
Orlistat, Progestin - Endometrial Neoplasms, Endometrial Cancer
Phase 2Not yet recruitingPeking University People's Hospital482026-07-012026-07-20
A Trial With EMP16 in Preparation for Late Phase Studies
EMP16-02 120 mg orlistat/40 mg acarbose, AlliĀ® 60 mg, Vi-SiblinĀ® S - Overweight or Obese, Obesity and Overweight
Phase 2Not yet recruitingEmpros Pharma AB392025-05-202025-05-28
Orlistat Overcoming Third-generation EGFR-TKI Resistance
Orlistat 120 mg - Lung Adenocarcinoma, Osimertinib
Phase 2Not yet recruitingPing Peng362025-02-162025-02-12
Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia
Orlistat, Placebo - Type 1 Hyperlipoprotenemia
Phase 2RecruitingUniversity of Texas Southwestern Medical Center282024-01-262026-07-21
Study Exploring the Supportive Effect of Acarbose in Weight Management
EMP16-120/40, MR orlistat 120 mg, Conventional orlistat 120 mg, - Overweight or Obesity
Phase 2UnknownEmpros Pharma AB3202023-04-182024-02-20
Orlistat for the Treatment of Type I Hyperlipoproteinemia
Orlistat - Hyperlipoproteinemia Type I, Hypertriglyceridemia
Phase 2CompletedUniversity of Texas Southwestern Medical Center22015-12-012023-02-08
Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia
SLx-4090 placebo, Orlistat Placebo, Orlistat - Type 1 Hyperlipoproteinemia
Phase 2TerminatedUniversity of Texas Southwestern Medical Center52015-11-012021-08-19
Ketogenic Diet Treatment of Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep Apnea
Ketogenic diet, Orlistat, Standardized diet - Obesity, Diabetes
Phase 2UnknownMid-Atlantic Epilepsy and Sleep Center, LLC1502014-01-012018-08-17
Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity
Metformin, Orlistat, Topiramate - Obesity, Metabolic Syndrome X
Phase 2TerminatedUniversity of Iowa1282011-03-012026-03-12
Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects
Velneperit 400 mg, Orlistat 120 mg, Orlistat Placebo - Obesity
Phase 2CompletedShionogi4862010-04-012018-05-09
Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients
orlistat - Obesity
Phase 2CompletedYazd Research & Clinical Center for Infertility802008-12-012021-04-01
Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women
Orlistat/Meal Replacement/Lifestyle Modification, Loestrin 1/20, Combination of treatments - Polycystic Ovary Syndrome
Phase 2CompletedMilton S. Hershey Medical Center2172008-09-012016-11-07
The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes
liraglutide, orlistat, placebo - Metabolism and Nutrition Disorder, Obesity
Phase 2CompletedNovo Nordisk A/S5642007-01-102017-11-01
Efficacy and Safety of ATL-962 in Obese Diabetics
ATL-962, Orlistat - Non-Insulin-Dependent Diabetes Mellitus, Obesity
Phase 2CompletedAlizyme6002004-12-012006-08-29
Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome
Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin, "Analimentary detoxication" - Metabolic Syndrome
Phase 1 / Phase 2CompletedNazarbayev University3512003-01-012015-11-30
Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases
Orlistat, Placebo - Diabetes Mellitus, Hypertension
Phase 2CompletedJack Yanovski2001998-05-012012-12-18

Conditions studied

Obesity (9)  ·  Diabetes Mellitus (3)  ·  Hypertension (3)  ·  Overweight (3)  ·  Diabetes Mellitus, Type 2 (2)  ·  Dyslipidemias (2)  ·  Hypertriglyceridemia (2)  ·  Metabolic Syndrome (2)  ·  Polycystic Ovary Syndrome (2)  ·  Adenocarcinoma of Lung (1)  ·  Endometrial Hyperplasia (1)  ·  Endometrial Neoplasms (1)  ·  Familial hyperchylomicronemia syndrome (1)  ·  Glucose Intolerance (1)  ·  Hyperlipoproteinemia Type I (1)

Sponsors

University of Texas Southwestern Medical Center (3)  ·  Empros Pharma AB (2)  ·  Alizyme (1)  ·  Jack Yanovski (1)  ·  Mid-Atlantic Epilepsy and Sleep Center, LLC (1)  ·  Milton S. Hershey Medical Center (1)  ·  Nazarbayev University (1)  ·  Novo Nordisk A/S (1)  ·  Peking University People's Hospital (1)  ·  Ping Peng (1)  ·  Shionogi (1)  ·  University of Iowa (1)  ·  Yazd Research & Clinical Center for Infertility (1)

Countries

United States (8)  ·  Sweden (3)  ·  Denmark (2)  ·  Finland (2)  ·  Netherlands (2)  ·  United Kingdom (2)  ·  Belgium (1)  ·  China (1)  ·  Czechia (1)  ·  Iran (1)  ·  Kazakhstan (1)  ·  Spain (1)

Top investigators

Abhimanyu Garg, MD (2)  ·  Abbas Aflatoonian, Professor (1)  ·  Abhimanyu G Garg, MD (1)  ·  Chandna Vasandani, Ph.D (1)  ·  Christos Coutifaris, M.D., Ph.D. (1)  ·  Gary L Pierce, PhD (1)  ·  Helena Litorp, MD, PhD (1)  ·  Jack A Yanovski, M.D. (1)  ·  Pavel Klein, M.D. (1)  ·  Peter Kopelman (1)  ·  Richard S Legro, M.D. (1)  ·  Tabynbayev Nariman, Professor (1)

Results publications

PMID 12105286, PMID 12126214, PMID 15112907, PMID 19461584, PMID 19853906, PMID 21844879, PMID 22140269, PMID 23942319, PMID 26210388, PMID 26401593, PMID 27172435, PMID 27253669, PMID 28163748, PMID 28386912, PMID 28473337, PMID 28950422, PMID 29659879, PMID 29718281, PMID 32968804, PMID 33059389, PMID 33059886, PMID 39952695, PMID 41349930